Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 3.33
TROV's Cash to Debt is ranked higher than
55% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.88 vs. TROV: 3.33 )
Ranked among companies with meaningful Cash to Debt only.
TROV' s Cash to Debt Range Over the Past 10 Years
Min: 1.83  Med: 49.59 Max: No Debt
Current: 3.33
Equity to Asset 0.57
TROV's Equity to Asset is ranked lower than
51% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.58 vs. TROV: 0.57 )
Ranked among companies with meaningful Equity to Asset only.
TROV' s Equity to Asset Range Over the Past 10 Years
Min: -4.07  Med: 0.51 Max: 0.75
Current: 0.57
-4.07
0.75
F-Score: 4
Z-Score: -0.32
M-Score: -3.35
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -9535.65
TROV's Operating margin (%) is ranked lower than
97% of the 195 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.48 vs. TROV: -9535.65 )
Ranked among companies with meaningful Operating margin (%) only.
TROV' s Operating margin (%) Range Over the Past 10 Years
Min: -9535.65  Med: -2022.18 Max: -1077.56
Current: -9535.65
-9535.65
-1077.56
Net-margin (%) -8518.66
TROV's Net-margin (%) is ranked lower than
97% of the 195 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.52 vs. TROV: -8518.66 )
Ranked among companies with meaningful Net-margin (%) only.
TROV' s Net-margin (%) Range Over the Past 10 Years
Min: -8518.66  Med: -2570.22 Max: -867.83
Current: -8518.66
-8518.66
-867.83
ROE (%) -78.31
TROV's ROE (%) is ranked lower than
81% of the 185 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.35 vs. TROV: -78.31 )
Ranked among companies with meaningful ROE (%) only.
TROV' s ROE (%) Range Over the Past 10 Years
Min: -104.97  Med: -102.41 Max: -78.31
Current: -78.31
-104.97
-78.31
ROA (%) -48.57
TROV's ROA (%) is ranked lower than
72% of the 207 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.00 vs. TROV: -48.57 )
Ranked among companies with meaningful ROA (%) only.
TROV' s ROA (%) Range Over the Past 10 Years
Min: -1064.26  Med: -182.08 Max: -48.57
Current: -48.57
-1064.26
-48.57
ROC (Joel Greenblatt) (%) -968.49
TROV's ROC (Joel Greenblatt) (%) is ranked lower than
82% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -11.24 vs. TROV: -968.49 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
TROV' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -17351.61  Med: -8320.86 Max: -968.49
Current: -968.49
-17351.61
-968.49
» TROV's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

TROV Guru Trades in Q2 2015

Jim Simons 132,100 sh (New)
» More
Q3 2015

TROV Guru Trades in Q3 2015

Jim Simons Sold Out
» More
Q4 2015

TROV Guru Trades in Q4 2015

First Eagle Investment 376,111 sh (New)
» More
Q1 2016

TROV Guru Trades in Q1 2016

First Eagle Investment Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with TROV

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:NAS:TTOO, NAS:CTSO, NAS:QTNT, OTCPK:EDTXF, OTCPK:EPGNY, NAS:PMD, NAS:CDNA, AMEX:VNRX, NAS:CEMI, NAS:VRML, NAS:AIQ, NAS:OXFD, NYSE:NVTA, OTCPK:AVDX, NAS:LNTH, OTCPK:ILIU, OTCPK:PRFMF, NYSE:ENZ, AMEX:PTN, NAS:CGIX » details
Traded in other countries:XE7A.Germany,
TrovaGene Inc is a development stage molecular diagnostic company. It focuses on the development and marketing of urine-based nucleic acid tests for patient/disease screening and monitoring.

TrovaGene Inc was incorporated in the State of Delaware on April 26, 2002 as Used Kar Parts, Inc. On July 2, 2004, the Company acquired Xenomics, a California corporation, which was developing and commercializing TrDNA technology. As part of the acquisition, its corporate name was changed to Xenomics, Inc. (Xenomics) The Company re-domesticated its state of incorporation from Florida to Delaware and its name was changed to Trovagene, Inc. It is a development stage molecular diagnostic company that focuses on the development and marketing of urine-based nucleic acid tests for patient/disease screening and monitoring. Its novel tests predominantly use transrenal DNA, or Tr-DNA, and transrenal RNA, or Tr-RNA. The Company is leveraging its proprietary urine-based molecular diagnostic technology for the detection of cell-free DNA and RNA originating from diseased cell death that can be isolated from urine and detected to improve disease management. These genetic materials are also collectively referred to as cell-free nucleic acids, which result when cells in the body die and release their DNA or RNA into the bloodstream. Its fundamental urine-based molecular diagnostic platform is protected by a intellectual property portfolio. The Company's developed intellectual property around cell-free nucleic acids in urine, the extraction of cell-free nucleic acids from urine, as well as novel assay designs, particularly its proprietary non-naturally occurring primers. As of February 28, 2014, its property portfolio consists of over 130 issued patents and over 47 pending patent applications. The Company faces direct competition in the area of transrenal cell-free DNA or RNA detection and analysis is precluded by its growing patent estate. Its competitors include medical diagnostic companies, of which have financial, technical, and marketing resources greater than its resources.

Ratios

vs
industry
vs
history
P/B 4.63
TROV's P/B is ranked lower than
62% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.49 vs. TROV: 4.63 )
Ranked among companies with meaningful P/B only.
TROV' s P/B Range Over the Past 10 Years
Min: 1.9  Med: 6.31 Max: 70.71
Current: 4.63
1.9
70.71
P/S 417.50
TROV's P/S is ranked lower than
99% of the 177 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.25 vs. TROV: 417.50 )
Ranked among companies with meaningful P/S only.
TROV' s P/S Range Over the Past 10 Years
Min: 85.71  Med: 284 Max: 916.43
Current: 417.5
85.71
916.43
Current Ratio 4.74
TROV's Current Ratio is ranked higher than
78% of the 201 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.42 vs. TROV: 4.74 )
Ranked among companies with meaningful Current Ratio only.
TROV' s Current Ratio Range Over the Past 10 Years
Min: 0.46  Med: 8.38 Max: 20.57
Current: 4.74
0.46
20.57
Quick Ratio 4.74
TROV's Quick Ratio is ranked higher than
83% of the 201 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.15 vs. TROV: 4.74 )
Ranked among companies with meaningful Quick Ratio only.
TROV' s Quick Ratio Range Over the Past 10 Years
Min: 0.46  Med: 8.38 Max: 20.57
Current: 4.74
0.46
20.57
Days Sales Outstanding 161.66
TROV's Days Sales Outstanding is ranked lower than
90% of the 155 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 66.20 vs. TROV: 161.66 )
Ranked among companies with meaningful Days Sales Outstanding only.
TROV' s Days Sales Outstanding Range Over the Past 10 Years
Min: 74.3  Med: 111.33 Max: 161.66
Current: 161.66
74.3
161.66
Days Payable 373.03
TROV's Days Payable is ranked higher than
95% of the 145 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 56.91 vs. TROV: 373.03 )
Ranked among companies with meaningful Days Payable only.
TROV' s Days Payable Range Over the Past 10 Years
Min: 373.03  Med: 18201.33 Max: 18201.33
Current: 373.03
373.03
18201.33

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price/Net Cash 5.69
TROV's Price/Net Cash is ranked higher than
72% of the 64 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.65 vs. TROV: 5.69 )
Ranked among companies with meaningful Price/Net Cash only.
TROV' s Price/Net Cash Range Over the Past 10 Years
Min: 3.25  Med: 7.25 Max: 208.67
Current: 5.69
3.25
208.67
Price/Net Current Asset Value 5.51
TROV's Price/Net Current Asset Value is ranked higher than
67% of the 117 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.23 vs. TROV: 5.51 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
TROV' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 3.21  Med: 7.13 Max: 156.5
Current: 5.51
3.21
156.5
Price/Tangible Book 4.64
TROV's Price/Tangible Book is ranked higher than
55% of the 152 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.63 vs. TROV: 4.64 )
Ranked among companies with meaningful Price/Tangible Book only.
TROV' s Price/Tangible Book Range Over the Past 10 Years
Min: 3.08  Med: 6.71 Max: 63.88
Current: 4.64
3.08
63.88
Price/Median PS Value 1.47
TROV's Price/Median PS Value is ranked lower than
76% of the 165 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.99 vs. TROV: 1.47 )
Ranked among companies with meaningful Price/Median PS Value only.
TROV' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.42  Med: 1.01 Max: 2.55
Current: 1.47
0.42
2.55
Earnings Yield (Greenblatt) (%) -25.72
TROV's Earnings Yield (Greenblatt) (%) is ranked lower than
79% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.20 vs. TROV: -25.72 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
TROV' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -84.19  Med: 0 Max: 0
Current: -25.72
-84.19
0

More Statistics

Revenue (TTM) (Mil) $0.36
EPS (TTM) $ -1.18
Beta0.33
Short Percentage of Float12.70%
52-Week Range $2.85 - 7.58
Shares Outstanding (Mil)30.15

Analyst Estimate

Dec16 Dec17
Revenue (Mil $) 2 5
EPS ($) -1.39 -1.31
EPS w/o NRI ($) -1.39 -1.31
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for NAS:TROV

Headlines

Articles On GuruFocus.com
Why People Lose Money Investing And What You Can Do About It Jul 29 2015 

More From Other Websites
TROVAGENE, INC. Files SEC form 8-K, Other Events Aug 17 2016
Blue Cross Blue Shield Illinois to Cover Trovera™ Liquid Biopsy Tests Aug 17 2016
Blue Cross Blue Shield Illinois to Cover Trovera™ Liquid Biopsy Tests Aug 17 2016
ETF’s with exposure to TrovaGene, Inc. : August 16, 2016 Aug 16 2016
TrovaGene, Inc. :TROV-US: Earnings Analysis: Q2, 2016 By the Numbers : August 15, 2016 Aug 15 2016
TROVAGENE, INC. Financials Aug 12 2016
TROVAGENE, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Aug 09 2016
Trovagene to Attend the 2016 Avondale Partners Healthcare 1-1 Conference Aug 09 2016
Trovera™ Urine Liquid Biopsy Test Provides EGFR Status to Inconclusive Tissue Biopsy: Case Report... Aug 09 2016
Trovera™ Urine Liquid Biopsy Test Provides EGFR Status to Inconclusive Tissue Biopsy: Case Report... Aug 09 2016
TrovaGene upgraded by Cantor Fitzgerald Aug 08 2016
Edited Transcript of TROV earnings conference call or presentation 4-Aug-16 9:00pm GMT Aug 06 2016
TrovaGene (TROV) Loss Narrows Y/Y, Trovera Holds Promise Aug 05 2016
Trovagene reports 2Q loss Aug 04 2016
Trovagene reports 2Q loss Aug 04 2016
TROVAGENE, INC. Files SEC form 8-K, Results of Operations and Financial Condition Aug 04 2016
Trovagene Reports Second Quarter 2016 Financial Results and Accomplishments Aug 04 2016
Trovagene Reports Second Quarter 2016 Financial Results and Accomplishments Aug 04 2016
TROVAGENE, INC. Files SEC form 10-Q, Quarterly Report Aug 04 2016
Q2 2016 Trovagene Inc Earnings Release - 4:00 pm ET Aug 04 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)